The fetal tight junction molecule claudin 6 (CLDN6) is virtually absent from any normal tissue, whereas it is aberrantly and frequently expressed in various cancers of high medical need.
Introduction
Cytotoxic T cells are considered to be the most potent effector cells of the immune system. The idea of using bispecific antibodies to redirect circulating T cells to tumor sites in vivo and engaging them with cancer cells emerged in the 1980s. [1] [2] [3] [4] Meanwhile, catumaxomab, an anti-EPCAM/anti-CD3 bispecific antibody based on a full IgG-like format, has been approved for the treatment of malignant ascites caused by epithelial cancers. 5, 6 Single chain variants are engineered by fusing single chain variable fragments (scFv) of different specificities by a flexible linker to obtain bi-(scFv) 2 , such as the anti-CD19/anti-CD3 bi-(scFv) 2 blinatumomab. 7 Very recently, the FDA approved blinatumomab (BLINCYTO) for treatment of relapsed/refractory B-cell precursor ALL [8] [9] [10] [11] making it the first approved immunotherapy against leukemia.
Cell killing induced by bi-(scFv) 2 is not MHC-restricted and does not require costimulatory signals. 12 Upon bi-(scFv) 2 -mediated engagement of a tumor cell with a T cell, an immunological synapse is formed. As a consequence, T cells are activated, proliferate, undergo polyclonal expansion and upregulate various immunomodulatory molecules. 13, 14 Bi-(scFv) 2 -mediated effects have been described as highly potent and strictly target dependent. 15 Accordingly, the tumor cell selectivity of the target molecule defines the safety profile of a bispecific T-cell engager. One major obstacle for exploitation of this promising platform technology is the scarcity of cancer cell specific surface molecules, in particular for non-hematological cancers of highest medical need. Catumaxomab can, so far, only be administered intraperitoneally for palliative treatment of epithelial cancer derived malignant ascites, as intravenous administration is associated with dose limiting on-target effects on the epithelial organs. development, as in healthy adult tissues it is transcriptionally silenced, [17] [18] [19] [20] [21] [22] [23] a fact which has led to consideration of CLDN6 as circulating marker for pregnancy. 24 In various cancer types such as ovarian, lung, gastric, breast and pediatric cancers, CLDN6 expression is aberrantly activated. 20, 21, 23, 25, 30 Thus, CLDN6 is an ideal target for antibody approaches of high potency. In fact, IMAB027, an immune effector mobilizing full IgG1 antibody, has entered clinical development and is being tested in patients with advanced ovarian cancer (NCT02054351). 31 This paper describes the preclinical validation of 6PHU3, the first-in-class T-cell-engaging bispecific molecule targeting CLDN6-positive tumor cells. To our knowledge, 6PHU3 is the bispecific T-cell engager with the highest cancer-cell selectivity in non-hematological malignancies and may tap into patient populations, who thus far cannot profit from bispecific antibody treatment.
Results
6PHU3 produced by mammalian cells binds selectively to both CLDN6 and CD3 6PHU3 (Fig. 1A ) and bi-(scFv) 2 control proteins -combining the binding site for human CLDN6 or an irrelevant tumor target with anti-human CD3 -were purified to obtain single bands of 53-55 kDa (Fig. 1B) .
Before the functional investigation began, the selected human tumor target cell lines PA-1 and OV-90 were confirmed by qPCR to be CLDN6-positive (CLDN6 C ) and MDA-MB-231/luc to be CLDN6-negative (CLDN6 -) (Fig. 1C) . It is noteworthy that PA-1 and OV-90 cell lines express lower levels of CLDN6 transcript compared to primary human ovarian cancer specimens.
Specific and robust concentration-dependent binding of 6PHU3 to PA-1 and OV-90 cells but not to the CLDN6 -control cells was demonstrated by flow cytometry (Fig. 1D) . Analogously, 6PHU3 bound specifically to human but not to murine CD3. It is important to mention that 6PHU3 is cross-reactive with murine CLDN6 (data not shown). Bispecificity of 6PHU3 for human CLDN6 and human CD3 was further confirmed by an ELISA based on simultaneous detection of both binding sites (Fig. 1E) . In summary, this data shows that 6PHU3 efficiently engages both T-cells and CLDN6 + target cells.
6PHU3 mediates strong T-cell activation and specific lysis of CLDN6 C target cells
Next, we analyzed the effects of 6PHU3 on effector and on target cells. T-cell clustering as an indicator of T-cell activation, was observed within 24 h of adding 6PHU3 to cultures of T cells and PA-1 target cells ( Fig. 2A) but not with CLDN6 -targets. Further, 6PHU3 induced a concentration-dependent and profound activation of CD3 C T cells only in the presence of target cells as shown by flow cytometry (Fig. 2B) . Upregulation of early (CD69) and late activation markers (CD25) was already significant at 0.01 ng/mL 6PHU3 (p < 0.02). The maximum of about 75% of activated T cells was reached at a concentration of 100 ng/mL 6PHU3 within 48 h of co-incubation.
To analyze proliferation, CFSE-labeled T cells were co-incubated with CLDN6
C or CLDN6 -target cells C/¡ 6PHU3 for 72 h. T-cell proliferation was 6PHU3 concentration-dependent and only occurred in the presence of CLDN6 C cells (Fig. 2C) . At a concentration of 10 ng/mL 6PHU3, 60-70% of T cells were found to proliferate.
To assess the capability of 6PHU3 to mediate specific tumor cell lysis, we performed a luciferase-based in vitro cytotoxicity assay using PBMC from three independent donors and determined dose/response relationships over 48 h (Fig. 2D) . Specific lysis of PA-1/luc and OV-90/luc cells but not of the CLDN6 -control cell line were mediated by 6PHU3. Efficient lysis was obtained and was donor and effector to target ratio dependent ( Table 1) .
At an E:T ratio of 1:1 robust killing of PA-1/luc but not of OV-90/luc was observed. A maximum of 70% PA-1/luc or 55% OV-90/luc cells were killed at an E:T of 5:1 and 85% or 70% at an E:T of 10:1, respectively. Half-maximal lysis concentrations (EC 50 ) were in the pg/mL range at all E:T ratios except for the 1:1 ratio in the case of OV-90/luc cells.
In summary, 6PHU3 is highly potent and strongly mediates efficient T-cell activation, proliferation and cytotoxicity at dose levels in pg/mL range exclusively in the presence of CLDN6-expressing target cells.
T cells engaged by 6PHU3 acquire a pro-inflammatory, cytotoxic type-1 phenotype
To study 6PHU3-engaged T cells in more detail, we conducted cDNA expression analysis upon co-incubation of T cells, bi-(scFv) 2 and target cells (Fig. 3A , the full data set is shown in Fig. S1 ). 6PHU3 T-cell engagement significantly elevated mRNA transcript levels of various T-cell activation markers and cytokines at a concentration of 5 ng/mL. Upregulation was most prominent for granzyme B (GZMB), CD137 (TNFRSF9A), CD25 (IL2RAA), IL12RB2, IFNg and IL-17A, which indicate activated, cytotoxic effectors and a general mostly inflammatory phenotype. The transcription of T H 2-cell cytokines IL-10, IL-21, IL-5, IL-4, IL-22 and IL-13, associated with stimulated CD4 C T cells, were highly increased. IL-6 and TGFß levels, in contrast, were not altered. Cytokine upregulation was dependent on the presence of both 6PHU3 and targetpositive cells. Only at 6PHU3 concentrations above 500 ng/mL -which is far higher than the efficacious concentration range for cell killing -did we detect modest and reversible upregulation of cytokine mRNA in the absence of CLDN6 by 6PHU3 alone.
Cytokine data was further confirmed on a protein level by measuring release of several of the cytokines into the supernatant by ELISA. After 24 h of incubation with 5 or 500 ng/mL 6PHU3, high levels of IFNg, IL-2, TNFa, (Fig. 3B ), but not of IL-6 (data not shown), were measured exclusively in the presence of both 6PHU3 and CLDN6 C . In summary, our data show that soon after engagement to target cells via 6PHU3, T cells are highly activated and acquire a pro-inflammatory effector phenotype. 2 were captured by a CD3-mimicking peptide. Detection was conducted by an antibody specific for the anti-CLDN6 scFv, and a 2nd detection antibody. ABS indicates absorption; APC, allophycocyanin; bi-(scFv) 2 , bispecific single chain variable fragment; CA, carcinoma; c, concentration; ctrl, control; H, 6xHis-tag; hu, human; LL, long linker (15-18 amino acids); mu, murine; Sec, secretion signal; SL, short linker (five amino acids); V L , variable light chain; V H , variable heavy chain; WB, western blot. , treatment was started with 200 mg/kg 6PHU3 -due to typical fast clearance of bi-(scFv) 2 either daily or three times/week -or with controls (daily vehicle or control bi-(scFv) 2 ) for a total of 38 d (Fig. 4A ). In the 'treatment' groups that received effectors and 6PHU3, significant tumor growth retardation was observed starting after day 7 of 6PHU3 dosing, leading to nearly complete tumor eradication in all but one of the mice that was treated only three times per week (Fig. 4B) . Four mice had to be sacrificed because of graft-vs.-host (GvH) reaction prior to potential relapse incidence. Five mice remained tumor free for another 18-43 d before onset of GvH reaction after treatment was discontinued on day 55. Three mice had a tumor relapse with the earliest being 25 d after the last 6PHU3 injection. Recurrent tumor specimens of relapsed mice were found to express CLDN6 in 5-40% of tumor cells and displayed low numbers of infiltrating human T cells (data not shown).
Median survival of all control groups ranged between 18 and 31 d, whereas the 6PHU3 treatment groups survived significantly longer with a median of 85 and 87 d (p < 0.0001) (Fig. 4C) .
Tumors of the mice in the 'no effector' and 'control' groups showed homogeneous CLDN6 expression in non-necrotic tumor areas and low numbers of infiltrating T cells (Fig. 4D) . In tumors of 6PHU3-treated mice, CLDN6
C cells were diminished and CLDN6 C areas were surrounded by organized, strong T-cell infiltrates as identified by anti-CD3 IHC staining. Similar results were obtained in a PA-1 xenograft study (Fig. S2 ) in which the overall CLDN6 expression was lower compared to OV-90 xenografts. Here, the treatment time had to be kept shorter (25 d) due to early GvH reactions in all groups. All except for one tumor showed growth arrest at volumes of 50-300 mm 3 . In summary, 6PHU3 treatment proved to be highly efficient against advanced tumors in aggressive xenograft mouse models and conferred a survival benefit.
Treatment with 6PHU3 reshapes the tumor microenvironment and increases immune cell infiltration
To characterize tumor-infiltrating lymphocytes recruited by 6PHU3, we set up a second treatment experiment (Fig. 5A) . NSG mice were s.c. inoculated with OV-90 carcinoma cells and engrafted with human PBMC or PBS as a control ('no effector' mice) 31 d later. 11 d post PBMC or PBS injection tumors had a median size of 420 mm 3 and treatment was initiated. PBMC engrafted mice were treated i.p. with vehicle, 200 mg/kg bi-(scFv) 2 or 6PHU3 for eight consecutive days. The 'no effector' mice were treated with vehicle only. Mice were sacrificed and tumors were analyzed using flow cytometry and gene expression analysis.
Flow cytometric analysis showed a 2-5-fold stronger infiltration of CD3 C T cells into tumors of PBMC-engrafted and 6PHU3-treated mice as compared to controls (Fig. 5B ). CD4 cDNA expression analysis of the tumors confirmed and further extended the mapping of 6PHU3-specific effects (Fig. 5C ). T-cell subset markers CD16a, CD8
C , CD127, 
CD4
C and CD62L (SELL) indicated infiltration by gd, cytotoxic, mature, T H 1/T H 2 and T N . T-cell activation markers (CD137 (TNFRSF9A), CD152 (CTLA4), CD212 (IL12RB1), CD69, CD25 (IL2RAa), CD28) were significantly upregulated in response to 6PHU3 as were granzyme B (GZMB) and perforin 1 (PRF1) as markers of high cytotoxicity, CD27 as a marker of T EM as along with CD279 (PDCD1) and CD154 (CD40LG) specifying terminally activated T cells.
The cytokine pattern indicated the presence of T H 17 T cells (IL17A), T H 1-cells with lytic activity (IFNg, IL21) and of T H 2-cells (IL10, IL5), whereas IL-6 and TNF mRNA levels were not induced by 6PHU3. T-cell specific transcription factors RORC (T H 17-cells), TBX21a .T H 1-cells), eomesodermin (EOMES, T CM ) and GATA3 (T H 2-cells) were increased. mRNAs for the chemokine receptors CCR5, CCR2 and CXCR3a involved in T-cell proliferation were augmented, as was chemokine ligand CCL3 mRNA. We did not find significant differences in CCR7 (T N or T CM ), TGFB1 and FOXP3 (T reg ) encoding mRNA levels.
CLDN6 mRNA level was lowest in the 6PHU3 treatment group, further confirming depletion of target-positive cancer cells.
In summary, 6PHU3 treatment appears to extensively reshape the tumor microenvironment toward an inflammatory response, including infiltration of tumors with T EM .
Discussion
The objective of this study was to characterize the primary pharmacodynamics of 6PHU3, the first recombinant CD3-/ CLDN6-bispecifc scFv-antibody. Key findings are as follows:
First, our data shows that 6PHU3 is highly potent in mobilizing resting CD3-expressing T cells. As a consequence, T cells undergo proliferation and acquire an activated, pro-inflammatory, T EM phenotype as demonstrated by transcript profiling and cell surface markers. We found that 6PHU3 mediates cell killing with high efficiency. EC 50 values are in the pg/mL range at low E:T ratios of 1:1 to 5:1. This indicates that 6PHU3- engaged T cells execute serial killing as is also claimed for other similar compounds such as blinatumomab. 13, 32, 33 Secondly, we showed that the in vitro pharmacodynamics of 6PHU3, in conjunction with human PBMCs, translates into remarkable antitumor effects in vivo in highly aggressive xenograft tumor models. Treatment of mice bearing CLDN6-expressing tumors results in an almost complete tumor elimination and profoundly prolonged survival, whereas treatment with the control bi-(scFv) 2 does not induce reduction of tumor size.
Thirdly, even though assessment of safety was not the objective of this study, findings on several levels indicate that 6PHU3 is well tolerated and safe. 6PHU3-mediated effects are strictly target dependent and require bispecific binding to both CLDN6 and CD3. Monospecific binding of the control bi-(scFv) 2 to CD3-expressing T cells in the absence of tumor target-independent binding does not lead to unspecific activation of the T cells. In our study, the treatment of T cells with 100-fold higher 6PHU3 concentration than the effective dose used in vitro has neither in the presence or absence of CLDN6 -cells led to upregulation of genes linked to T-cell activation and has only led to short term upregulation of inflammatory cytokines. An important contribution to the lack of on-target or off-target toxicity of 6PHU3 in mouse experiments is to be attributed to the choice of CLDN6 as target. The vast majority of reports indicate that CLDN6 is exclusively embryofetal and not expressed at all in healthy adolescent human and mouse tissues. [17] [18] [19] 24, 25, 29, 34, 38 However, there is also some conflicting data, reporting e.g. transcript detection in human hepatocytes. 39 As a matter of fact, a comprehensive and broad profiling of CLDN6 across body maps of both species with valid definitions of positivity has not been published so far. Our own tissue profiling data (manuscript in preparation) conducted with strictly CLDN6-specific primers and antibody reagents, respectively, supports lack of CLDN6 expression in healthy adolescent human cells and tissues. Moreover, even though preliminary, safety monitoring of the ongoing first-in-human testing of the investigational medicinal product IMAB027, from which 6PHU3 has been derived, in more than 40 patients has not indicated on-target hepatic toxicity (manuscript in preparation). 31, 40 Safety of CLDN6-based targeting approaches remain to be more firmly investigated.
Another important finding is the strong specific effect of 6PHU3 on the tumor microenvironment. Tumors of animals treated with 6PHU3 show a far stronger infiltration with CD3 C T cells compared to control groups. Within these infiltrates activated CD4
C and CD8 C populations and profoundly enriched PD-1-expressing T cells were found in the 6PHU3-treated group only. PD-1 upregulation is frequently linked to initiation of a negative feedback loop to limit inflammation 28, 29 or T-cell exhaustion due to persistent antigenic stimulation. 30, 41 Recent data, however, supports that PD-1 C T cells likely represent a particular differentiation stage or trafficking ability rather than exhaustion. 11, 42, 43 T cells in tumors of 6PHU3-treated mice have the T EM phenotype, as also reported previously for the anti-EpCAM MT110 13,32-34 and anti-CD19 blinatumomab. 8 T reg activation, which should be prevented by bispecific antibodies, was not detected in the tumor lesions. In response to 6PHU3, type-1 cytokines IL-2, TNFa and IFNg that are known to be involved in activation of cell-mediated antitumor responses were expressed at the tumor site, whereas type-2 cytokines IL-4 and TGFb fostering a pro-tumorigenic state [45] [46] [47] [48] were not expressed. In summary, these data justify further exploration of 6PHU3 to potentially gain a therapeutic that is highly specific and efficient for the treatment of CLDN6 C solid cancers.
Materials and methods

Cells and cell culture
Target cells were the endogenously CLDN6-expressing (CLDN6 Codon optimized scFv sequences were generated by gene synthesis (GeneArt AG). Anti-CLDN6 V H and V L domains directed against the first extracellular loop of CLDN6 (provided by Ganymed Pharmaceuticals AG) 49 were linked by a 15 amino acid encoding linker sequence ((G 4 S 1 ) 3 ). This anti-CLDN6 scFv was joined by a (G 4 S 1 ) 1 peptide linker coding sequence to anti-CD3e scFv 2, 41 and equipped with a secretion signal sequence at the 5 0 -end and a 6xHis-tag sequence at the 3 0 -end. pcDNA3.1/6PHU3 or control bi-(scFv) 2 were produced in HEK293 clonal producer cell lines grown in DMEM, 10% FCS supplemented with 0.8 mg/mL G418 (Invitrogen). 50 Bi-(scFv) 2 culture supernatants harvested from HEK293 producer cell lines in multiple layer Cell Factories (Nunc) were subjected to immobilized metal affinity chromatography (IMAC) (GE Healthcare Life Sciences). 50 Eluted proteins were dialyzed against vehicle buffer consisting of 200 mM L-Arginine-monohydrochloride (Roth) in H 2 O, pH 7.4.
Bi-(scFv) 2 quality was tested by Coomassie brilliant blue staining and Western blot analysis 50 carried out using monoclonal anti-6xHis-tag antibody (Dianova) and Fc-specific secondary peroxidase-conjugated goat-anti-mouse IgG antibody (Sigma Aldrich). 0 -AAG GAG GGC GAT GAC ACA GAG-3 0 ) expression was determined using the DDCt-method by normalization to the housekeeping gene HPRT1 (sense 5 0 -TGA CAC TGG CAA AAC AAT GCA-3 0 ; antisense 5 0 -GGT CCT TTT CAC CAG CAA GCT-'3) and calibration to the mean value of CLDN6
-human tissue cDNA.
FACS binding assay
OV-90, PA-1, MDA-MB-231/luc (negative control) cells, human T cells and murine T cells (negative control) were incubated with purified 6PHU3. 6PHU3 binding was detected with a primary anti-6xHis-tag antibody (Dianova) followed by incubation with an APC-conjugated goat-anti-mouse secondary antibody (Jackson Immuno Research). Staining controls were either the primary and secondary antibodies or the secondary antibody alone in the absence of 6PHU3. Dead cells were separated by 7-Actinomycin D (7-AAD (Beckman Coulter)) staining. Sample processing was performed on a FACSCantoII (BD Biosciences) and with FlowJo 7 software (Tree Star).
Bispecific ELISA
Streptavidin plates (Nunc) were coated with a biotinylated custom-made CD3-mimicking peptide (JPT Peptide Technologies, patent application submitted). After blocking with 3% BSA, bi-(scFv) 2 was applied and an antibody against the CLDN6-recognizing domain of 6PHU3 (Ganymed Pharmaceuticals AG) was added for the detection with an AP-labeled anti-mouse antibody (Jackson Immuno Research) and a pNPP substrate based reaction. 
T-cell activation and proliferation assay
Data was analyzed by a sigmoidal dose-response (variable slope) algorithm integrated into PRISM 6 software (GraphPad).
For microscopic analysis, the assay was performed in transparent 48- 3 or weight loss of 20% e.g., in case of GvH reaction.
For generation of Kaplan-Meier survival curves, the day of treatment start was considered day 0.
Immunohistochemistry (IHC)
IHC analysis was described previously. 20 Briefly, 3 mm tissue sections of xenograft tumors were incubated with a primary rabbit anti-CLDN6 antibody (IBL-America) or a polyclonal anti-CD3 antibody (Abcam) followed by incubation with PowerVision polymer-HRP conjugated anti-Rabbit secondary antibody (Immunologic). Binding reactions were visualized by the Vector NovaRED kit (Vector Laboratories Ltd.) and hematoxylin counterstaining (Carl Roth). Stained tumor sections were scanned with the Leica SCN 400 (Leica Biosystems).
Flow cytometric analysis of TIL
Single tumor cell suspensions were generated by manual disruption. Two subsets of anti-human antibodies were used. Subset 1: CD45, CD3, CD25, CD69, CD62L, CD45RA, CD14, CD16, CD19 (all BD Biosciences), CD8
C (eBioscience), CD4
C and CD197 (both BioLegend). Subset 2: CD45, CD3, CD25, CD45RA, CD103, CD127, CD279, FoxP3 (all BD Bioscience), CD8 C (eBioscience) and CD4 C (BioLegend). Dead cells were stained with LIVE/DEAD Fixable Blue Dead Cell Stain Kit (Invitrogen). Samples were processed on an LSRFortessa flow cytometer (BD Biosciences) and data was analyzed as whole percentage of live singlet cells using FlowJo software 7.
Gene expression analysis of xenograft tumors
RNA from tumor slices was isolated by QIAzol Lysis Reagent and the TissueLyser II, followed by the RNeasy Ò Lipid Tissue Mini Kit procedure including the RNeasy Ò Mini Kit spin purification method (Qiagen). cDNA synthesis and gene expression analysis via Fluidigm BioMark TM HD system was performed as described above. Data sets were evaluated according to the DDCt-method by normalization to the housekeeping gene HPRT1 and calibration to the mean values of the 'no effector' reference tumor samples.
Statistical analysis
Kaplan-Meier survival curves were compared by using logrank (Mantel-Cox) test, T-cell activation by One-way ANOVA and TIL flow cytometry data by one-tailed Students t-test (unpaired). Differences between groups were considered significant in cases where p < 0.05. All analyses were integrated in GraphPad PRISM 6.
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